# BLAZE-Limiting Approach in NMOSD

> **NCT06888622** · — · COMPLETED · sponsor: **Huashan Hospital** · enrollment: 9 (actual)

## Conditions studied

- Neuromyelitis Optica Spectrum Disorders (NMOSD)

## Interventions

- **DRUG:** Eculizumab administration

## Key facts

- **NCT ID:** NCT06888622
- **Lead sponsor:** Huashan Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2023-10-01
- **Primary completion:** 2025-03-01
- **Final completion:** 2025-03-03
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2025-03-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06888622

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06888622, "BLAZE-Limiting Approach in NMOSD". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT06888622. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*